| Literature DB >> 31312863 |
L Vranken1,2,3, C E Wyers1,2,3, B van Rietbergen4,5, J H M Driessen3,6,7, P P M M Geusens7,8,9, H M J Janzing10, R Y van der Velde1,2,3, J P W van den Bergh11,12,13,14,15.
Abstract
We evaluated the association between prevalent vertebral fractures and bone micro-architecture and strength measured using HR-pQCT in postmenopausal women with a recent non-vertebral fracture visiting the Fracture Liaison Service. The presence and severity of prevalent vertebral fracture reflect generalized bone deterioration.Entities:
Keywords: Fracture Liaison Service; HR-pQCT; Vertebral fractures
Mesh:
Year: 2019 PMID: 31312863 PMCID: PMC6719323 DOI: 10.1007/s00198-019-05081-9
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Fig. 1Flowchart of patient inclusion
General characteristics of patients with a recent NVF at the FLS according to the presence of prevalent vertebral fracture
| Women ( | |||
|---|---|---|---|
| No VF ( | ≥ 1 VF Gr. ≥ 1 ( | ||
| Age (years) | 62.9 ± 7.8 | 67.7 ± 8.4 | .000* |
| Height (cm) | 1.6 ± 0.1 | 1.6 ± 0.1 | .295 |
| Weight (kg) | 74.6 ± 14.3 | 72.7 ± 12.1 | .296 |
| BMI (kg/m2) | 27.6 ± 5.0 | 27.1 ± 4.0 | .474 |
| FRAX major osteoporotic fractures | 82 (31.1) | 30 (40.5) | .126 |
| LS aBMD (g/cm2) | 0.93 ± 0.14 | 0.91 ± 0.17 | .388 |
| FN aBMD (g/cm2) | 0.70 ± 0.11 | 0.67 ± 0.10 | .032* |
| TH aBMD (g/cm2) | 0.85 ± 0.13 | 0.81 ± 0.12 | .028* |
| Normal BMD | 72 (27.3) | 13 (17.6) | .113 |
| Osteopenia | 135 (51.1) | 38 (51.4) | |
| Osteoporosis | 57 (21.6) | 23 (31.1) | |
| Previous fracture after age 50 years | 48 (18.2) | 36 (48.6) | .000* |
| Parent fractured hip | 17 (6.4) | 4 (5.4) | .999 |
| Current smoking | 36 (13.6) | 9 (12.2) | .741 |
| Glucocorticoids | 12 (4.5) | 3 (4.1) | .999 |
| Rheumatoid arthritis | 10 (3.8) | 4 (5.4) | .516 |
| Secondary osteoporosis | 70 (26.5) | 21 (28.4) | .749 |
| Alcohol ≥ 3 units/day | 4 (1.5) | 1 (1.4) | .999 |
| History or current use of anti-osteoporosis drugs | 21 (8.0) | 19 (26.0) | .000* |
| Self-reported use of anti-osteoporosis medication, | 18 (6.9) | 18 (24.7) | .000* |
| Type, | |||
| Alendronic acid | 11 (61.1) | 9 (50.0) | .887 |
| Risedronic acid | 5 (27.8) | 6 (33.3) | |
| Zoledronic acid | 0 (0.0) | 1 (5.6) | |
| Unknown | 2 (11.1) | 2 (11.1) | |
| Duration (year), mean ± SD# | 4.5 ± 2.7 | 5.2 ± 4.1 | .577 |
| Current, | 3 (16.7) | 10 (55.6) | .015* |
| History, | 15 (83.3) | 8 (44.4) | |
| Time since cessation of treatment (year), mean ± SD# | 2.6 ± 2.6 | 1.1 ± 2.3 | .109 |
| Falls past year | 79 (30.0) | 21 (28.8) | .834 |
Variables are presented as mean ± standard deviation or number (percentage). P value < 0.05 is considered significant (*)
#In patients who have ever used anti-osteoporosis medication
VF, vertebral fracture; BMI, body mass index; LS, lumbar spine; FN, femoral neck, TH, total hip; aBMD, areal bone mineral density
HR-pQCT parameters at the distal tibia and radius according to presence and severity of prevalent VFs in women with a recent NVF at the FLS
| Presence of prevalent VFs | Severity of prevalent VFs | ||||
|---|---|---|---|---|---|
| Radius ( | No VF ( | ≥ 1 VF Gr. ≥ 1 ( | ≥ 1 VF Gr. 1 ( | ≥ 1 VF Gr. 2–3 ( | |
| vBMD | |||||
| Dtot (mgHA/cm3) | 270 ± 62 | 233 ± 55* | 236 ± 56* | 230 ± 55* | .000 |
| Dtrab (mgHA/cm3) | 121 ± 39 | 96 ± 37* | 101 ± 33* | 91 ± 41* | .000 |
| Dcort (mgHA/cm3) | 892 ± 62 | 872 ± 69 | 870 ± 64 | 875 ± 75 | .068 |
| Micro-architecture | |||||
| Tb.N (mm−1) | 1.20 ± 0.26 | 1.02 ± 0.31* | 1.06 ± 0.28* | 0.97 ± 0.34* | .000 |
| Tb.Th (mm) | 0.22 ± 0.02 | 0.23 ± 0.02 | 0.23 ± 0.02 | 0.23 ± 0.02 | .362 |
| Tb.Sp (mm) | 0.86 ± 0.27 | 1.15 ± 0.68* | 1.04 ± 0.46* | 1.28 ± 0.86* | .000 |
| Ct.Po (%) | 0.86 ± 0.56 | 0.88 ± 0.49 | 0.86 ± 0.43 | 0.90 ± 0.56 | .899 |
| Ct.Th (mm) | 0.92 ± 0.18 | 0.85 ± 0.15 | 0.85 ± 0.15 | 0.84 ± 0.15 | .012 |
| Ct.Po.Dm (mm) | 0.19 ± 0.03 | 0.20 ± 0.03 | 0.20 ± 0.04 | 0.20 ± 0.03 | .359 |
| Biomechanical | |||||
| F.Ult (kN) | 2.81 ± 0.72 | 2.49 ± 0.55* | 2.58 ± 0.51 | 2.40 ± 0.59* | .002 |
| Scomp (kN/mm) | 52 ± 13 | 47 ± 10* | 49 ± 9 | 45 ± 10* | .002 |
| Tibia ( | No VF ( | ≥ 1 VF Gr. ≥ 1 ( | ≥ 1 VF Gr. 1 ( | ≥ 1 VF Gr. 2–3 (n = 35) | |
| vBMD | |||||
| Dtot (mgHA/cm3) | 243 ± 54 | 209 ± 46* | 211 ± 42* | 207 ± 52* | .000 |
| Dtrab (mgHA/cm3) | 140 ± 38 | 119 ± 34* | 121 ± 31* | 117 ± 37* | .000 |
| Dcort (mgHA/cm3) | 837 ± 73 | 813 ± 72 | 820 ± 66 | 806 ± 77 | .035 |
| Micro-architecture | |||||
| Tb.N (mm−1) | 1.19 ± 0.23 | 1.08 ± 0.29* | 1.10 ± 0.28 | 1.06 ± 0.30* | .004 |
| Tb.Th (mm) | 0.25 ± 0.02 | 0.25 ± 0.02 | 0.25 ± 0.02 | 0.25 ± 0.02 | .405 |
| Tb.Sp (mm) | 0.87 ± 0.33 | 1.02 ± 0.45* | 0.99 ± 0.44 | 1.05 ± 0.46* | .004 |
| Ct.Po (%) | 3.22 ± 1.32 | 3.22 ± 1.37 | 3.04 ± 1.12 | 3.41 ± 1.59 | .505 |
| Ct.Th (mm) | 1.21 ± 0.25 | 1.10 ± 0.21* | 1.10 ± 0.19* | 1.11 ± 0.22 | .005 |
| Ct.Po.Dm (mm) | 0.23 ± 0.03 | 0.23 ± 0.04 | 0.23 ± 0.03 | 0.24 ± 0.04 | .426 |
| Biomechanical | |||||
| F.Ult (kN) | 8.00 ± 1.62 | 7.14 ± 1.49* | 7.27 ± 1.35* | 7.00 ± 1.63* | .000 |
| Scomp (kN/mm) | 147 ± 32 | 131 ± 28* | 133 ± 26* | 128 ± 31* | .000 |
Variables are presented as mean ± SD. P value < 0.05 is considered significant
*P < 0.05 compared with patients without a prevalent VF (with Bonferroni correction for multiple testing)
VF, vertebral fracture; vBMD, volumetric bone mineral density; Dtot, total density; Dtrab, trabecular density; Dcort, cortical density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Ct.Th, cortical thickness; Ct.Po, cortical porosity; Ct.Po.Dm, cortical pore diameter; F.Ult, ultimate failure load; Scomp, compression stiffness
Associations between the presence, severity, and number of prevalent vertebral fractures and HR-pQCT parameters in women with a recent NVF at the FLS
| Presence of prevalent VFs | Severity of prevalent VFs | ||||
|---|---|---|---|---|---|
| Radius | No VF | VF ( | Gr. 1 VF ( | Gr. 2–3 VF ( | |
| vBMD | |||||
| Dtot (mgHA/cm3) | Ref. | − 16.66 (− 31.93, − 1.39)* | − 10.05 (− 28.65, 8.56) | − 26.10 (− 47.65, − 4.56)* | .015* |
| Dtrab (mgHA/cm3) | Ref. | − 11.75 (− 21.91, − 1.58)* | − 7.66 (− 20.06, 4.73) | − 17.57 (− 31.92, − 3.22)* | .012* |
| Dcort (mgHA/cm3) | Ref. | − 9.88 (− 26.38, 6.62) | − 7.58 (− 27.74, 12.58) | − 13.16 (− 36.50, 10.18) | .216 |
| Micro-architecture | |||||
| Tb.N (1/mm) | Ref. | − 7.83 (− 15.19, − 0.46)* | − 5.50 (− 14.49, 3.49) | − 11.15 (− 21.56, − 0.75)* | .024* |
| Tb.Th (mm) | Ref. | 0.20 (− 0.27, 0.67) | 0.16 (− 0.41, 0.74) | 0.25 (− 0.42, 0.91) | .400 |
| Tb.Sp (mm) | Ref. | 8.98 (0.68, 17.29)* | 5.21 (− 4.91, 15.33) | 14.37 (2.66, 26.08)* | .014* |
| Ct.Po (%) | Ref. | 3.26 (− 16.09, 22.61) | 0.07 (− 23.57, 23.70) | 7.82 (− 19.55, 35.19) | .628 |
| Ct.Th (mm) | Ref. | − 3.10 (− 7.70, 1.51) | − 1.62 (− 7.24, 4.00) | − 5.21 (− 11.71, 1.30) | .117 |
| Ct.Po.Dm (mm) | Ref. | 3.41 (− 1.59, 8.41) | 2.24 (− 3.86, 8.34) | 5.08 (− 1.99, 12.14) | .136 |
| Biomechanical | |||||
| F.Ult (kN) | Ref. | − 0.15 (− 0.32, 0.02) | − 0.08 (− 0.28, 0.13) | − 0.26 (− 0.49, − 0.02)* | .038* |
| Scomp (kN/mm) | Ref. | − 2.47 (− 5.49, 0.55) | − 1.02 (− 4.69, 2.66) | − 4.55 (− 8.80, − 0.29)* | .045* |
| Tibia | No VF | VF ( | Gr. 1 VF ( | Gr. 2–3 VF ( | |
| vBMD | |||||
| Dtot (mgHA/cm3) | Ref. | − 21.35 (− 33.04, − 9.66)* | − 16.83 (− 31.23, − 2.42)* | − 27.58 (− 44.02, − 11.13)* | .000* |
| Dtrab (mgHA/cm3) | Ref. | − 16.55 (− 25.22, − 7.66)* | − 13.88 (− 24.70, − 3.05)* | − 19.96 (− 32.32, − 7.61)* | .000* |
| Dcort (mgHA/cm3) | Ref. | − 1.65 (− 19.28, 15.97) | 3.7 (− 18.26, 25.20) | − 8.69 (− 33.50, 16.12) | .637 |
| Micro-architecture | |||||
| Tb.N (1/mm) | Ref. | − 7.18 (− 13.69, − 0.67)* | − 6.81 (− 14.85, 1.22) | − 7.68 (− 16.85, 1.49) | .040* |
| Tb.Th (mm) | Ref. | − 0.28 (− 0.84, 0.27) | − 0.40 (− 1.09, 0.28) | − 0.12 (− 0.90, 0.66) | .479 |
| Tb.Sp (mm) | Ref. | 9.31 (1.92, 16.70)* | 8.74 (− 0.38, 17.86) | 10.09 (− 0.32, 20.50) | .018* |
| Ct.Po (%) | Ref. | − 8.90 (− 21.20, 3.39) | − 8.10 (− 23.28, 7.07) | − 10.00 (− 27.32, 7.33) | .167 |
| Ct.Th (mm) | Ref. | − 5.90 (− 11.69, − 0.11)* | − 4.49 (− 11.63, 2.65) | − 7.83 (− 15.99, 0.32) | .036* |
| Ct.Po.Dm (mm) | Ref. | 0.95 (− 2.71, 4.62) | 0.20 (− 4.32, 4.72) | 1.99 (− 3.17, 7.15) | .492 |
| Biomechanical | |||||
| F.Ult (kN) | Ref. | − 0.55 (− 0.90, − 0.21)* | − 0.47 (− 0.89, − 0.04)* | − 0.67 (− 1.15, − 0.18)* | .002* |
| Scomp (kN/mm) | Ref. | − 10.88 (− 17.56, − 4.21)* | − 9.20 (− 17.43, − 0.97)* | − 13.20 (− 22.59, − 3.80)* | .001* |
All analyses are adjusted for age, weight, height, type of recent non-vertebral fracture type (major osteoporotic fracture vs. other fractures), previous fractures at or above the age of 50 years, anti-osteoporosis medication (never vs. history vs. current), and femoral neck areal BMD
No prevalent VF is used as the reference group. *Significant
VF, vertebral fracture; Ref., reference; vBMD, volumetric bone mineral density; Dtot, total density; Dtrab, trabecular density; Dcort, cortical density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Ct.Th, cortical thickness; Ct.Po, cortical porosity; Ct.Po.Dm, cortical pore diameter; F.Ult, ultimate failure load; Scomp, compression stiffness